Clinical Trial Update: Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating telotristat etiprate (LX1606) for symptomatic carcinoid syndrome not controlled by stable-dose octreotide; study completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Syndrome

Drugs mentioned

• Telotristat Etiprate (telotristat etiprate)

Snippet

Sponsor: Lexicon Pharmaceuticals | Conditions: Carcinoid Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2018-12-26